| Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy E Heister, V Neves, C Tîlmaciu, K Lipert, VS Beltrán, HM Coley, SRP Silva, ... Carbon 47 (9), 2152-2160, 2009 | 322 | 2009 |
| Higher dispersion efficacy of functionalized carbon nanotubes in chemical and biological environments E Heister, C Lamprecht, V Neves, C Tîlmaciu, L Datas, E Flahaut, B Soula, ... ACS nano 4 (5), 2615-2626, 2010 | 233 | 2010 |
| Drug loading, dispersion stability, and therapeutic efficacy in targeted drug delivery with carbon nanotubes E Heister, V Neves, C Lamprecht, SRP Silva, HM Coley, J McFadden Carbon 50 (2), 622-632, 2012 | 188 | 2012 |
| Oral Immunization with Recombinant Lactobacillus plantarum Induces a Protective Immune Response in Mice with Lyme Disease B Del Rio, RJ Dattwyler, M Aroso, V Neves, L Meirelles, JFML Seegers, ... Clinical and Vaccine Immunology 15 (9), 1429-1435, 2008 | 85 | 2008 |
| Antibody approaches to treat brain diseases V Neves, F Aires-da-Silva, S Corte-Real, MARB Castanho Trends in Biotechnology 34 (1), 36-48, 2016 | 69 | 2016 |
| Uptake and release of double‐walled carbon nanotubes by mammalian cells V Neves, E Heister, S Costa, C Tîlmaciu, E Borowiak‐Palen, CE Giusca, ... Advanced Functional Materials 20 (19), 3272-3279, 2010 | 62 | 2010 |
| Design of double-walled carbon nanotubes for biomedical applications V Neves, E Heister, S Costa, C Tîlmaciu, E Flahaut, B Soula, HM Coley, ... Nanotechnology 23 (36), 365102, 2012 | 59 | 2012 |
| AFM imaging of functionalized carbon nanotubes on biological membranes C Lamprecht, I Liashkovich, V Neves, J Danzberger, E Heister, M Rangl, ... Nanotechnology 20 (43), 434001, 2009 | 59 | 2009 |
| Comprehensive seroprofiling of sixteen B. burgdorferi OspC: implications for Lyme disease diagnostics design L Ivanova, I Christova, V Neves, M Aroso, L Meirelles, D Brisson, ... Clinical immunology 132 (3), 393-400, 2009 | 55 | 2009 |
| Peptibodies: An elegant solution for a long‐standing problem M Cavaco, MARB Castanho, V Neves Peptide Science 110 (1), e23095, 2018 | 53 | 2018 |
| Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? M Cavaco, D Gaspar, M ARB Castanho, V Neves Pharmaceutics 12 (1), 62, 2020 | 39 | 2020 |
| Novel peptides derived from Dengue virus capsid protein translocate reversibly the blood–brain barrier through a receptor-free mechanism V Neves, F Aires-da-Silva, M Morais, L Gano, E Ribeiro, A Pinto, S Aguiar, ... ACS Chemical Biology 12 (5), 1257-1268, 2017 | 38 | 2017 |
| A New Noncanonical anionic peptide that translocates a cellular blood–brain barrier model S Neves-Coelho, RP Eleutério, FJ Enguita, V Neves, MARB Castanho Molecules 22 (10), 1753, 2017 | 36 | 2017 |
| Bioconjugate Supramolecular Pd2+ Metallacages Penetrate the Blood Brain Barrier In Vitro and In Vivo B Woods, RDM Silva, C Schmidt, D Wragg, M Cavaco, V Neves, ... Bioconjugate Chemistry 32 (7), 1399-1408, 2021 | 34 | 2021 |
| The use of antibody-antibiotic conjugates to fight bacterial infections M Cavaco, MARB Castanho, V Neves Frontiers in Microbiology 13, 835677, 2022 | 31 | 2022 |
| To what extent do fluorophores bias the biological activity of peptides? A practical approach using membrane-active peptides as models M Cavaco, C Pérez-Peinado, J Valle, RDM Silva, JDG Correia, D Andreu, ... Frontiers in bioengineering and biotechnology 8, 552035, 2020 | 28 | 2020 |
| Penetrating the blood-brain barrier with new peptide–porphyrin conjugates having anti-HIV activity DA Mendonça, M Bakker, C Cruz-Oliveira, V Neves, MA Jiménez, ... Bioconjugate Chemistry 32 (6), 1067-1077, 2021 | 26 | 2021 |
| Cellular localization, accumulation and trafficking of double-walled carbon nanotubes in human prostate cancer cells V Neves, A Gerondopoulos, E Heister, C Tîlmaciu, E Flahaut, B Soula, ... Nano Research 5, 223-234, 2012 | 26 | 2012 |
| Conjugation of a blood brain barrier peptide shuttle to an Fc domain for brain delivery of therapeutic biomolecules M Cavaco, S Frutos, P Oliete, J Valle, D Andreu, MARB Castanho, ... ACS Medicinal Chemistry Letters 12 (11), 1663-1668, 2021 | 19 | 2021 |
| Platform technology to deliver prophylactic molecules orally: An example using the Class A select agent Yersinia pestis B Del Rio, JL Fuente, V Neves, R Dattwyler, JFML Seegers, ... Vaccine 28 (41), 6714-6722, 2010 | 18 | 2010 |
